Rapidly Infusing Oral Mucosal CBD Composition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current pain treatment methods, particularly for neuropathic pain, face challenges due to the limited effectiveness of opioids leading to addiction and side effects, and cannabidiol (CBD) lacks scientific validation for pain relief due to issues with administration, bioavailability, and patient compliance.

Innovation Solution

A rapidly infusing composition using gelatin and sugar alcohol as a binder and excipient system for oral mucosal administration of CBD, providing a rapid disintegration profile and high bioavailability, allowing for accurate dosing and improved patient compliance.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If opioids are used to treat neuropathic pain, then pain relief is achieved, but addiction and side effects increase

Engineering Contradiction:

Improvepain relief effectivenessVSAvoidaddiction and side effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent extracts the therapeutic benefit of pain relief from opioid medications while eliminating the harmful components (addiction and side effects) by using CBD as an alternative active therapeutic ingredient that does not produce opioid-like addiction or severe side effects

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent employs a rapidly infusing oral mucosal composition that delivers CBD quickly and effectively, providing pain relief without the long-term dependency issues of opioids, effectively replacing a long-acting problematic solution with a short-acting safe alternative

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Quantity of substance

If CBD is administered traditionally, then it is available for therapeutic use, but bioavailability is low due to first-pass metabolism

Engineering Contradiction:

ImproveCBD dosageVSAvoidbioavailability

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent uses the oral mucosa as an intermediary absorption route that bypasses the gastrointestinal tract and first-pass liver metabolism, allowing CBD to enter systemic circulation directly through the rich vascular supply of the oral mucosal tissues

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the administration route from gastrointestinal to oral mucosal, and modifies the physical state of CBD through micronization (reducing particle size to 1-50 μm) to enhance dissolution and absorption rate, thereby dramatically improving bioavailability

Inventive Principle:

Principle #35Parameter changes

3Ease of operation

If CBD is administered orally, then it is easy to administer, but disintegration time is slow and patient compliance is poor

Engineering Contradiction:

Improveadministration convenienceVSAvoiddisintegration time

Core Design Contradiction:

Ease of operationVSLoss of time

Solution Approach 1:

The patent changes the physical and chemical parameters of the formulation by using gelatin and sugar alcohol in specific ratios (gelatin: 10-35 wt.%, sugar alcohol: 5-35 wt.%) to create a matrix that rapidly disintegrates in oral cavity conditions, reducing disintegration time to 1-30 seconds

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite material system combining gelatin, sugar alcohol, and micronized CBD that leverages the rapid disintegration properties of the gelatin-sugar alcohol matrix to deliver the therapeutic ingredient quickly, maintaining ease of oral administration while eliminating slow disintegration issues

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition achieves rapid and effective pain relief with high bioavailability of CBD, reducing the need for opioids and improving patient compliance by bypassing first-pass metabolism and providing quick therapeutic onset.

Implementation Method 1

a rapidly infusing composition comprising (a) a pharmaceutically acceptable binder and/or excipient system comprising gelatin and a sugar alcohol

Methodology Applied

Scientific EffectAbsorption (physical): Absorption (physical)

Implementation Method 2

administering to the subject in need thereof, via the oral mucosa, a rapidly infusing composition... providing a rapid disintegration profile and high bioavailability, allowing for accurate dosing and improved patient compliance by bypassing first-pass metabolism

Methodology Applied

Scientific EffectAbsorption (physical): Absorption (physical)

Data Source

PatentUS20230285303A1Rapidly infusing platform and compositions for therapeutic treatment in humans

Publication Date: 2023.09.14 ORCOSA INC

AI summary

A composition and method of treatment in a subject, whereby the subject is administered via the oral mucosa a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and mannitol, and (b) a therapeutically effective amount of an active therapeutic ingredient (ATI). Preferably, a composition and method of treating pain in a subject, whereby the subject is administered via the oral mucosa a rapidly infusing composition that includes (a) a pharmaceutically acceptable binder and/or excipient system containing gelatin and mannitol, and (b) a therapeutically effective amount cannabidiol (CBD).